Larvol Delta - March-Biosciences-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-MB105-FirstinClass-CD5-CART-Cell-Therapy-for-TCell-Lymphoma

MB-105 - March Bio

https://www.globenewswire.com/news-release/2025/04/22/3065415/0/en/March-Biosciences-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-MB-105-First-in-Class-CD5-CAR-T-Cell-Therapy-for-T-Cell-Lymphoma.html

Apr 22, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next